N-[(1RS,2RS)-2-(4-chlorophenyl)-1-methyl-3-{3-(phenylcarbamoyl)-5-isoxazolyl}propyl]-N-(2-naphthylmethyl)carbamoylmethylsuccinic acid | 178416-27-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-[(1RS,2RS)-2-(4-chlorophenyl)-1-methyl-3-{3-(phenylcarbamoyl)-5-isoxazolyl}propyl]-N-(2-naphthylmethyl)carbamoylmethylsuccinic acid
• 英文别名: 2-[2-[[3-(4-Chlorophenyl)-4-[3-(phenylcarbamoyl)-1,2-oxazol-5-yl]butan-2-yl]-(naphthalen-2-ylmethyl)amino]-2-oxoethyl]butanedioic acid
• CAS: 178416-27-8
• 化学式: C₃₇H₃₄ClN₃O₇
• 分子量: 668.146
• InChiKey: QYRFTXVKAKKAEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  48
• 可旋转键数：
  14
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  150
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• N,N-DISUBSTITUTED AMIC ACID DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0805154A1

  公开（公告）日：1997-11-05

  The present invention relates to a compound of the formula (I): wherein Ar1, Ar2, Ar3 and Ar4 represent an aryl group or a heteroaromatic ring group; A represents a hydrocarbon group which may be substituted; X and Y represent an oxygen atom, a sulfur atom, a carbonyl group or a group of the formula -CHRa- (wherein Ra is a hydrogen atom or a lower alkyl group) or -NRb- (wherein Rb is a hydrogen atom or a lower alkyl group), or X and Y together represent a vinylene group or an ethynylene group; R1, R2, R3, R8 and R9 represent a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a lower alkoxy group; R4 and R5 represent a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkyl group, a lower hydroxyalkyl group, a lower fluoroalkyl group or a lower alkoxy group; R6 is a lower alkyl group; and R7 is a hydrogen atom or a lower alkyl group, provided that when one of X and Y is an oxygen atom, a sulfur atom or a group of the formula -NRb-, the other is a carbonyl group or a group of the formula -CHRa-, its pharmaceutically acceptable salt or ester, and an antitumor agent containing it as an active ingredient.

  本发明涉及一种式（I）化合物： 其中 Ar1、Ar2、Ar3 和 Ar4 代表芳基或杂芳环基团；A 代表可被取代的烃基；X和Y代表氧原子、硫原子、羰基或式-CHRa-（其中Ra为氢原子或低级烷基）或-NRb-（其中Rb为氢原子或低级烷基）的基团，或X和Y共同代表乙烯基或乙炔基； R1、R2、R3、R8和R9代表氢原子、卤素原子、羟基、低级烷基或低级烷氧基；R4 和 R5 代表氢原子、卤素原子、羟基、氨基、硝基、氰基、羧基、低级烷氧基羰基、氨基甲酰基、低级烷基氨基甲酰基、低级烷基、低级羟烷基、低级氟烷基或低级烷氧基； R6 是低级烷基；和 R7 是氢原子或低级烷基，条件是当 X 和 Y 中的一个是氧原子、硫原子或式 -NRb- 的基团时，另一个是羰基或式 -CHRa- 的基团、其药学上可接受的盐或酯，以及含有它作为活性成分的抗肿瘤剂。
• MEDICINAL COMPOSITION
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0856315A1

  公开（公告）日：1998-08-05

  The present invention relates to an antitumor or anti-AIDS composition containing a protein-farnesyltransferase inhibitor and an agent which decreases farnesyl pyrophosphate in vivo as active ingredients.

  本发明涉及一种抗肿瘤或抗艾滋病组合物，其活性成分含有一种蛋白-法尼基转移酶抑制剂和一种能减少体内焦磷酸法尼基的制剂。
• METHODS OF TREATMENT OF OCULAR NEOVASCULARIZATION
  申请人：——

  公开号：US20020006967A1

  公开（公告）日：2002-01-17

  The present invention includes methods for treatment and prophylaxis of eye disorders and injuries, particularly treatment and prophylaxis of ocular neovascularization and disorders, especially a vasculopathy that affects retinal or chorodial vessels. The methods of the invention in general comprise administration of a therapeutically effective amount of a compound that inhibits farnesyl-protein transferase to a subject suffering from or susceptible to ocular neovascularization or associated disorder.

  本发明包括治疗和预防眼部疾病和损伤的方法，特别是治疗和预防眼部新生血管和疾病，尤其是影响视网膜或脉络膜血管的血管病变。本发明的方法一般包括向患有或易患眼部新生血管或相关疾病的受试者施用治疗有效量的抑制法尼基蛋白转移酶的化合物。
• PROTEIN-FARNESYLTRANSFERASE INHIBITORS IN COMBINATION WITH HMGCOA-REDUCTASE-INHIBITORS FOR THE TREATMENT OF AIDS
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0856315B1

  公开（公告）日：2005-08-24
• US5849747A
  申请人：——

  公开号：US5849747A

  公开（公告）日：1998-12-15